Follicular Lymphoma Presenting With Symptomatic Bone Involvement: A Clinicopathologic and Molecular Analysis of 16 Cases.
Détails
ID Serval
serval:BIB_8D5FC967934E
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Follicular Lymphoma Presenting With Symptomatic Bone Involvement: A Clinicopathologic and Molecular Analysis of 16 Cases.
Périodique
Modern pathology
ISSN
1530-0285 (Electronic)
ISSN-L
0893-3952
Statut éditorial
Publié
Date de publication
04/2024
Peer-reviewed
Oui
Volume
37
Numéro
4
Pages
100440
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
Primary bone lymphoma (PBL) is rare and mostly represented by diffuse large B-cell lymphomas (DLBCL). Follicular lymphoma (FL), albeit commonly disseminating to the bone marrow, rarely presents primarily as bone lesions. Here, we studied 16 patients (12 men:4 women, median age 60 years) who presented with bone pain and/or skeletal radiologic abnormalities revealing bone FL. Lesions were multifocal in 11 patients (spine ± appendicular skeleton), and unifocal in 5 patients (femoral, tibial, or vertebral). An infiltrate of centrocytes and centroblasts (CD20+ CD5- CD10+ BCL2+ BCL6+) with abundant reactive T cells and an increased reticulin fibrosis massively replaced the marrow spaces between preserved bone trabeculae. The pattern was diffuse ± nodular, often with paratrabecular reinforcement and/or peripheral paratrabecular extension. Ki-67 was usually <15%. Two cases had necrosis. BCL2 rearrangement was demonstrated in 14 of 14 evaluable cases (with concomitant BCL6 rearrangement in one). High-throughput sequencing revealed BCL2, KMT2D, and TNFRSF14 to be the most frequently mutated genes. After staging, 5 qualified for PBL (3 limited stage) and 11 had stage IV systemic FL. All patients received rituximab ± polychemotherapy as firstline treatment, and 7 received local therapy (6 radiotherapy and 2 surgery). Three patients experienced transformation to DLBCL. At the last follow-up (15/16, median 48 months), 11 patients achieved complete remission, including all cases with PBL and most patients with limited extraosseous disease (3-year progression-free survival 71%). One patient died of unrelated cause (3-year overall survival 91%). FL may manifest as a localized or polyostotic bone disease. A minority represent PBL, whereas most reveal systemic disease.
Mots-clé
Male, Humans, Female, Middle Aged, Lymphoma, Follicular/genetics, Lymphoma, Follicular/therapy, Lymphoma, Follicular/pathology, Lymphoma, Large B-Cell, Diffuse/pathology, Rituximab, Progression-Free Survival, Proto-Oncogene Proteins c-bcl-2/genetics, BCL2 rearrangement, bone lymphoma, follicular lymphoma, mutational profile
Pubmed
Web of science
Création de la notice
01/02/2024 15:32
Dernière modification de la notice
23/04/2024 5:59